Abstracts tagged "gout"

Abstract Number: 2063 • 2017 ACR/ARHP Annual Meeting
Relation of Serum Urate and Gout Duration to Tophi, Urate Deposition, and Inflammation
Ana Beatriz Vargas-Santos¹, S. Reza Jafarzadeh², Geraldo Castelar-Pinheiro¹, Nicola Dalbeth³, William J. Taylor⁴, Jaap Fransen⁵, Tim L. Jansen⁶, H. Ralph Schumacher⁷ and Tuhina Neogi², ¹Internal Medicine - Rheumatology, State University of Rio de Janeiro, Rio de Janeiro, Brazil, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³University of Auckland, Auckland, New Zealand, ⁴Department of Medicine, University of Otago, Wellington, New Zealand, ⁵Department of Rheumatolgy, Radboud University Medical Center, Nijmegen, Netherlands, ⁶Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ⁷Medicine, Rheumatology, U Penn & VA Med Ctr, Philadelphia, PA
Background/Purpose: Gout duration and serum urate (SU) levels are thought to influence development of tophi and chronic inflammatory gouty arthropathy, but the extent to which…
Abstract Number: 2847 • 2017 ACR/ARHP Annual Meeting
The Sons of Gout Study. Ultrasonographic Evaluation of Asymptomatic Monosodium Urate Crystal Deposition in Sons of People with Gout
Abhishek Abhishek¹, Wendy Jenkins¹, Philip Courtney², Adrian Jones³, Weiya Zhang⁴ and Michael Doherty⁵, ¹Devision of Rheumatology, University of Nottingham, NG5 1PB, England, ²Department of Rheumatology, Notingham, United Kingdom, ³Rheumatology Unit, Nottingham City Hospital, Nottingham Notts, United Kingdom, ⁴Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Nottingham, United Kingdom, ⁵Academic Rheumatology, University of Nottingham, Nottingham, Great Britain
Background/Purpose: Hyperuricemia and gout aggregate in families. The objectives of this study were to estimate the prevalence of asymptomatic monosodium urate (MSU) crystal deposition in…
Abstract Number: 1117 • 2017 ACR/ARHP Annual Meeting
the Absolute Risk of Clinically Diagnosed Gout By Serum Uric Acid Levels – Results from 30 Years Follow-up of the Malmö Preventive Project Cohort in Southern Sweden
Meliha C. Kapetanovic¹, Peter M Nilsson², Carl Turesson³, Martin Englund⁴, Nicola Dalbeth⁵, Lieke E.J.M. Scheepers⁶ and Lennart TH Jacobsson⁶, ¹Lund University, Skane University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ²Department of Clinical Sciences, Lund University, Skåne University Hospital Malmö, Sweden., Lund, Sweden, ³Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁴Clinical Sciences Lund, Orthopedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden, ⁵University of Auckland, Auckland, New Zealand, ⁶Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Hyperuricemia i.e. increased s-uric acid levels (s-UA), is established risk factor for clinical gout. Studies regarding the absolute and relative effect on population level…
Abstract Number: 2064 • 2017 ACR/ARHP Annual Meeting
The Nomenclature of Gout: A Content Analysis of Contemporary Medical Journals
David Bursill^1,2, William J. Taylor³, Robert Terkeltaub⁴ and Nicola Dalbeth⁵, ¹Medicine, University of Auckland, Auckland, New Zealand, ²School of Medicine, University of Adelaide, Adelaide, Australia, ³University of Otago, Wellington, New Zealand, ⁴Rheumatology, VA San Diego Healthcare System, San Diego, CA, ⁵University of Auckland, Auckland, New Zealand
Background/Purpose: Gout has been recognized and described since antiquity. However, the terms used to describe the disease lack standardization. The aim of this study was…
Abstract Number: 2848 • 2017 ACR/ARHP Annual Meeting
Improving Gout Outcomes: The Randomized Evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-Up) Study
Ted R. Mikuls¹, TC Cheetham², Gerald D. Levy³, Nazia Rashid⁴, Kimberly Low⁵, Brian W Coburn⁶, Kenneth Saag⁷, Lang Chen⁸ and Jeffrey R. Curtis⁹, ¹Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, ³Internal Medicine/Rheumatology, Kaiser Permanente Southern California, Downey, CA, ⁴Pharmacy Analytic Services, Kaiser Permanente Southern California, Downey, CA, ⁵Kaiser Permanente Southern California, Panorama City, CA, ⁶Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁷Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Allopurinol is a cornerstone therapy in gout management. Despite this, allopurinol use is suboptimal as providers often fail to follow the treat-to-target paradigm…
Abstract Number: 1119 • 2017 ACR/ARHP Annual Meeting
Uncontrolled Gout Patients with Higher Heart Failure Hospitalization Rates in US
Robert Morlock¹, Pierre Chevalier², An-Chen Fu³ and Douglas C.A. Taylor³, ¹YourCareChoice, Ann Arbor, MI, ²IMS Health, Zaventem, Belgium, ³Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by elevated serum uric acid (sUA). Elevated sUA is associated with worsened…
Abstract Number: 2070 • 2017 ACR/ARHP Annual Meeting
Evidence-Based Development of Criteria for Complete Response in Patients with Chronic Refractory Gout
Naomi Schlesinger¹, Puja Khanna², Anthony Yeo³ and Peter E. Lipsky⁴, ¹Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rheumatology, University of Michigan, Ann Arbor, MI, ³Horizon Pharma, Lake Forest, IL, ⁴AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: A Delphi exercise reached consensus on a definition for gout remission that included serum uric acid (sUA) <6 mg/dL, no flares, resolution of all…
Abstract Number: 2896 • 2017 ACR/ARHP Annual Meeting
Human Cartilage Influences the Crystallization of Monosodium Urate; Understanding the Link between Gout and Osteoarthritis
Ashika Chhana¹, Bregina Pool², Ally Choi¹, Ryan Gao¹, Mark Zhu¹, Jillian Cornish², Jacob Munro³ and Nicola Dalbeth⁴, ¹Medicine, University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Orthopaedics, Auckland City Hospital, Auckland, New Zealand, ⁴University of Auckland, Auckland, New Zealand
Background/Purpose: Monosodium urate (MSU) crystal deposition and gout flares frequently affect joints that have been damaged or are affected by osteoarthritis. The aim of…
Abstract Number: 1120 • 2017 ACR/ARHP Annual Meeting
Less Than Half of Patients Treated with High-Dose Allopurinol Reach Serum Uric Acid Target
Robert Morlock¹, Douglas C.A. Taylor² and Scott Baumgartner³, ¹YourCareChoice, Ann Arbor, MI, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA, ³drB Consulting, Spokane, WA
Background/Purpose: Although allopurinol is FDA approved for up to 800 mg per day and EMEA authorized for up to 900 mg per day, most patients…
Abstract Number: 2071 • 2017 ACR/ARHP Annual Meeting
A Novel Selective URAT1 Inhibitor, Tei-a, with Potent Uricosuric Property
Johji Nomura¹, Yoshimasa Takahashi², Kumiko Aoki², Naoki Hase² and Tsunefumi Kobayashi², ¹Teijin Institute for Bio-medical Research, TEIJIN PHARMA LIMITED, Tokyo, Japan, ²TEIJIN PHARMA LIMITED, Tokyo, Japan
Background/Purpose: Hyperuricemia, abnormally elevated level of serum uric acid, is associated with gout as well as other diseases including metabolic syndrome, hypertension, diabetic kidney disease.…
Abstract Number: 2950 • 2017 ACR/ARHP Annual Meeting
Validation of a Definition for Flare in Patients with Established Gout
Angelo L. Gaffo¹, Nicola Dalbeth², Kenneth Saag³, Jasvinder A. Singh⁴, Elizabeth J. Rahn¹, Amy S. Mudano⁵, Yi-Hsing Chen⁶, Ching-Tsai Lin⁷, Sandra Bourke², Worawit Louthrenoo⁸, Janitzia Vazquez-Mellado⁹, Hansel Hernández-Llinas¹⁰, Tuhina Neogi¹¹, Ana Beatriz Vargas-Santos¹², Geraldo Castelar-Pinheiro¹³, Rodrigo B. Chaves-Amorim¹³, Till Uhlig¹⁴, Hilde B Hammer¹⁴, Maxim Eliseev¹⁵, Fernando Perez-Ruiz¹⁶, Lorenzo Cavagna¹⁷, Geraldine M. McCarthy¹⁸, Lisa K. Stamp¹⁹, Martijin Gerritsen²⁰, Viktoria Fana²¹, Francisca Sivera²² and William J. Taylor²³, ¹Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Auckland, Auckland, New Zealand, ³Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Taichung Veterans General Hospital, Taichung, Taiwan, ⁷Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ⁸Div of Rheumatology, Dept of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁹Rheumatology, Hospital General de Mexico, Mexico City, Mexico, ¹⁰Hospital General de Mexico, Mexico City, Mexico, ¹¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ¹²Internal Medicine Department, Division of Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹³Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil, ¹⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁵V. A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation, ¹⁶Servicio de Reumatología, Vizcaya, Spain, ¹⁷Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ¹⁸Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ¹⁹University of Otago, Christchurch, New Zealand, ²⁰Westfries Gasthuis, Hoorn, Netherlands, ²¹Center for Rheumatology and Spine Diseases, Rigshospitalet , Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ²²Sección de Reumatología, Hospital General Universitario de Elda., Elda, Spain, ²³University of Otago, Wellington, New Zealand
Background/Purpose: A standardized validated definition for gout flares (or attacks) is not available. Two provisional definitions published in 2012 were based on patient-reported elements (patient-defined…
Abstract Number: 60 • 2017 ACR/ARHP Annual Meeting
Low and Moderate Intensity Exercise Suppresses Inflammatory Responses in an Acute Mouse Model of Gout and Suggests Therapeutic Efficacy
Nicholas A. Young¹, Kyle Jablonski², Juhi Sharma¹, Evelyn Thomas¹, Brian Snoad¹, Jeffrey Hampton³, Wael Jarjour¹ and Naomi Schlesinger⁴, ¹Department of Internal Medicine, Division of Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University Wexner Medical Center, Columbus, OH, ³Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Little is known regarding the potential benefits of exercise on managing acute gout. Consequently, recent clinical practice guidelines released by the American College of…
Abstract Number: 1121 • 2017 ACR/ARHP Annual Meeting
Allopurinol Treatment for Gout: How Long to Reach Serum Urate Goal?
Jean J. Lim^1,2, An-Chen Fu², Jami Giordano², David S. Reasner² and Douglas C.A. Taylor², ¹Tufts University School of Medicine, Botson, MA, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Urate-lowering therapy (ULT) is essential in chronic gout management. For decades, allopurinol has remained the most frequently prescribed ULT. Reaching a goal of serum…
Abstract Number: 2072 • 2017 ACR/ARHP Annual Meeting
A Pharmacokinetic and Pharmacodynamic Evaluation of URC102, a Potent and Selective Inhibitor of URAT1, after Single and Multiple Oral Administrations in Healthy Volunteers
Hyun A Lee¹, Sang-In Park¹, Seonghae Yoon², Makoto Onohara³, Jeongeun Choi⁴, Kyung-Sang Yu¹ and Howard Lee¹, ¹Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea, Republic of (South), ²Clinical Trials Center, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ³Science and Strategy, Translational Clinical Research, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan, ⁴JW Pharmaceutical Corporation, Seoul, Korea, Republic of (South)
Background/Purpose: URC102, a novel and potent inhibitor of human uric acid transporter 1 (hURAT1), is currently under clinical development to treat patients with gout. In…
Abstract Number: 76 • 2017 ACR/ARHP Annual Meeting
TNF-α Potentiates Uric Acid-Induced Interleukin-1β Secretion in Human Neutrophils
Shuzo Sato¹, Makiko Yashiro¹, Tomoyuki Asano¹, Tomohiro Koga², Eiji Suzuki¹, Hiroko Kobayashi¹, Hiroshi Watanabe¹ and Kiyoshi Migita³, ¹Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Fukushima Medical University School of Medicine, Fukushima, Japan
Background/Purpose: Gout is an inflammatory arthropathy due to the deposition of uric acid (monosodium urate: MSU) crystals in synovial tissue. MSU leads to activate nucleotide-binding…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].